Thursday, May 16, 2013

BRACE YOURSELF:IMMUNOTHERAPY IS COMING TO OVARIAN AND SOON TO PANCREATIC CANCERS!

YES, THE MAGIC BULLETS DREAMED REPORTEDLY BY PAUL EHRLICH ARE COMING TO CANCERS!
DMUC5754A HAS SHOWN SOME ACTIVITY IN OVARIAN CANCERS.  LIKE T-DM1, IT IS A CONJUGATE OF A DRUG (ONLY KNOWN AS MMAE) AND AN ANTIBODY TO MUC-16 PROTEIN WHICH IS EXPRESSED IN OVARIAN CANCER, SEE OUR DISCUSSION ON VARIOUS MUC !

REMEMBER: A HIGHER DOSE OF FASLODEX (500 MG vs 250MG) SHOWED A 19% REDUCTION IN RELATIVE RISK OF DEATH AND A MEDIAN SURVIVAL OF 26.4 MONTHS VS 22.3 MONTHS. SO CHOOSE TO GIVE 500 MG EVEN IN PATIENTS WHO HAD BEEN STARTED ON 250 MG BY SOMEBODY ELSE, KEEPING THEM ON THE DOSE MAY NOT BE THE BEST CHOICE FOR OUR PATIENTS! (ONLY MAYBE IF THE PATIENT HAS BEEN ON 250 MG FOR MORE THAN 50 MONTHS WHERE THE DIFFERENCE OF SURVIVAL SEEMS TO NO LONGER BE STATISTICALLY SIGNIFICANT!

DON'T BE FOOLED, BREAST CANCER IN YOUNGER WOMEN IS ON THE RISE AND THEREFORE YOUR CHANCE OF BEING CONFRONTED BY A YOUNG WOMAN WITH BREAST CANCER IS SOMEWHAT HIGHER EVERYDAY!

ADDING BORTEZOMIB TO STANDARD INDUCTION OF AML IS AN EXAMPLE OF TARGETING THERAPY IN-ROD INTO LEUKEMIA AND EARLY REPORTS SUGGEST IT IS SOMETHING TO FOLLOW. RESEARCHERS ARE LOOKING AT THE EXPRESSION OF CD 74 TO SEE IF IT WILL HELP PREDICT THE OUTCOME. WE WILL FOLLOW THIS FOR YOU!
Post a Comment